Physician profile
Gilbert Mbeo
NPI 1396024949
$5,845.05
in general payments reported to CMS, 2019-2025
45 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,285 · 2020: $109 · 2021: $143 · 2022: $636 · 2023: $1,371 · 2024: $1,258 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,424 · Travel and Lodging: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,424.40 |
| Travel and Lodging | $248.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $859.74 | 2022-2023 | Accurian, Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Boston Scientific Corporation | $780.01 | 2019 | |
| Abbvie INC. | $652.05 | 2023-2025 | |
| Nevro Corp. | $565.77 | 2019-2024 | Senza |
| Novartis Pharmaceuticals Corporation | $489.40 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $443.31 | 2024-2025 | Hyqvia |
| Vertos Medical, INC. | $179.00 | 2023 | Mild Device Kit |
| Spr Therapeutics, INC | $161.77 | 2022-2024 | Sprint Pns System |
| Axogen | $141.74 | 2025 | |
| Novocure INC. | $130.41 | 2021 | |
| Pfizer INC. | $127.36 | 2023-2025 | |
| Pacira Pharmaceuticals Incorporated | $95.85 | 2023-2024 | Iovera, Zilretta, Exparel |
| Otsuka America Pharmaceutical, INC. | $90.17 | 2024-2025 | Rexulti, Nuedexta |
| Eisai INC. | $89.21 | 2024-2025 | |
| Irras USA, INC. | $88.26 | 2020 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| F. Hoffmann-La Roche Ag | $80.00 | 2025 | |
| Grt US Holding, INC. | $79.15 | 2022 | |
| Curonix LLC | $64.91 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Amneal Pharmaceuticals LLC | $57.68 | 2025 | Crexont |
| Axsome Therapeutics, INC. | $52.12 | 2025 | Symbravo |
| Averitas Pharma INC. | $46.01 | 2023-2024 | Qutenza |
| Lilly USA, LLC | $44.44 | 2023-2025 | Emgality, Kisunla |
| Genentech USA, INC. | $41.91 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Collegium Pharmaceutical, INC. | $39.46 | 2023-2024 | Belbuca, Xtampza |
| Biogen, INC. | $36.84 | 2024 | Leqembi |
| Ceribell, INC. | $36.43 | 2024 | Pocket Eeg Device |
| Neurelis, INC. | $36.08 | 2021-2023 | Valtoco |
| Vertex Pharmaceuticals Incorporated | $32.84 | 2025 | |
| Alnylam Pharmaceuticals INC. | $29.89 | 2024 | Onpattro |
| Abbott Laboratories | $29.69 | 2023 | Proclaim |
| Nalu Medical, INC. | $27.00 | 2024 | Nalu Neurostimulation System |
| Argenx US, INC. | $26.54 | 2023 | Vyvgart |
| Avanos Medical | $25.81 | 2019 | |
| Brainsway USA INC | $24.13 | 2024 | Brainsway Deep Tms System |
| Csl Behring | $20.58 | 2020 | |
| Painteq LLC | $20.14 | 2024 | Painteq |
| Saluda Medical Americas, INC. | $19.43 | 2024 | Evoke |
| Merck Sharp & Dohme LLC | $18.51 | 2023 | Dificid, Zerbaxa, Recarbrio |
| Xtant Medical INC | $16.78 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.80 | 2022 | |
| Scilex Pharmaceuticals INC. | $15.76 | 2023 | Ztlido |
| Portola Pharmaceuticals, LLC | $13.07 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Mbeo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.